SCHEMBL3450104

SCHEMBL3450104

CSc1nc(Nc2ccc(F)c(S(C)(=O)=O)c2)ncc1Br

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 19/20 0.47
CDK2 P24941 19/20 0.47
KDR P35968 16/20 0.46
GRM4 Q14833 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450272 0.85 GRM4 (0.44) CDK1CDK2KDRGRM4
SCHEMBL3449221 0.84 KDR (0.42) CDK1CDK2KDR
SCHEMBL3350947 0.81 MAPK1 (0.51)
SCHEMBL3448943 0.79 PTK2 (0.50) CDK1CDK2KDR
SCHEMBL3448927 0.76 CDK1 (0.44) CDK1CDK2KDR
SCHEMBL3450501 0.75 HDAC3 (0.44) CDK1CDK2KDR
SCHEMBL3450174 0.74 IDH1 (0.37) CDK1CDK2KDRGRM4
SCHEMBL2514896 0.72 GRM4 (0.48) CDK2GRM4
SCHEMBL4584347 0.72 IGF1R (0.48) CDK1CDK2KDR
SCHEMBL3344725 0.72 CA12 (0.50) CDK1CDK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CDK1 1871/4885CDK2 2258/4885KDR 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.